Product Name: Brk (443-450) pS446+pY447
Product Number: PE-04AHP00
Size: 200 µg      Price:65.00
1 mg      $US129.00
5 mg      283.00
Peptide Name: Brk (443-450) pS446+pY447

Product Use: Services as a blocking peptide for use with the BRK-pS446+pY447 rabbit polyclonal antibody (Cat. No.: AB-PK547) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminus of the kinase. Phosphorylation inhibits phosphotransferase activity and regulates molecular association.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: SFT-pS-pY-ENP

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1277.14 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Brk - pS446+pY447 phosphosite-specific antibody (Cat. No.: AB-PK547)

Scientific Background: Brk (PTK6) is a protein-tyrosine kinase of the TK group and Src family. It is a non-receptor kinase that is implicated as a regulator of several intracellular signalling pathways involved in cellular differentiation, epithelial maintenance, and tumourigenesis. The activity of Brk appears to be dependent upon the cell type and intracellular localization of the protein. In non-tumour cells, Brk activity promotes cellular differentiation and apoptosis, while in cancer tissue Brk activity sensitizes cells to growth promoting signals leading to increased cell proliferation, anchorage-independent cell survival, and cell migration/invasion. The nuclear form of the protein is thought to be involved in regulating epithelial growth. The 451-amino acid sequence of the Brk protein resembles that of a Src family kinase, containing a SH3, SH2, and a catalytic domain. However unlike Src kinases, the N-terminal domain of the Brk protein does not contain a myristolyation domain, indicating different regualtory mechanisms. Brk mRNA is expressed at high levels in the colon, small intestine, and prostate as well as at low levels in some fetal tissues.